Low-Dose IL-2 Therapy to Shift the Treg/Teff Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies for autoimmune and inflammatory diseases risk aggravating the disease due to the activation of effector T cells, despite their potential to stimulate regulatory T cells, posing safety concerns.
Innovation Solution
Administering low doses of IL-2 to selectively stimulate regulatory T lymphocytes (Tregs) without substantially inducing effector T lymphocytes (Teffs), thereby shifting the Treg/Teff balance towards Tregs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of IL-2 are administered to stimulate regulatory T cells, then the therapeutic effect on autoimmune diseases is improved, but effector T cells are activated which aggravates the disease
Solution Approach 1:
The patent applies parameter changes by administering IL-2 at low doses (0.01-10 million international units per day, preferably 0.1-1 million international units per day) instead of high doses. This dosage parameter change selectively stimulates Treg cells without substantially activating Teff cells, thereby achieving therapeutic effect while avoiding disease aggravation. The low dose regime shifts the balance between Treg and Teff cells towards Tregs, resolving the contradiction between therapeutic benefit and harmful side effects.
2Reliability
If IL-2 is administered to treat autoimmune diseases, then immune response modulation is achieved, but IL-2-associated side effects occur
Solution Approach 1:
The patent reduces IL-2 dosage to low levels (0.01-10 million international units per day) to achieve immune response modulation while minimizing side effects. This parameter change allows sufficient Treg cell stimulation for therapeutic effect while avoiding the harmful side effects associated with high-dose IL-2 administration, such as excessive immune activation and systemic toxicity.
Solution Approach 2:
The patent creates a selective local quality effect by using low-dose IL-2 to preferentially stimulate Treg cells with high IL-2 receptor expression while sparing Teff cells. This selective action achieves immune response modulation in the desired direction (increasing suppressive Treg activity) without triggering the harmful side effects that would result from broad immune cell activation.
3Quantity of substance
If conventional IL-2 dosing is used, then effector T cell activation occurs, but regulatory T cell expansion is insufficient
Solution Approach 1:
The patent resolves this contradiction by changing the dosage parameter to low levels (0.01-10 million international units per day). At this reduced dosage, IL-2 selectively expands Treg cells through their high-affinity IL-2 receptors while the lower concentration is insufficient to substantially activate Teff cells. This parameter optimization achieves adequate Treg expansion for therapeutic effect without triggering harmful Teff activation.
Solution Approach 2:
The patent applies partial action by administering a sub-optimal dose of IL-2 that is sufficient to stimulate Treg cells (which have high IL-2 receptor expression) but insufficient to substantially activate Teff cells. This partial stimulation approach achieves the desired Treg expansion while avoiding excessive immune activation and associated harmful effects.
Data Source
AI summary
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.